SS Innovations International Inc. (NASDAQ: SSII) has expanded its global footprint by supporting the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo. The program utilizes the company's SSi Mantra 3.0 surgical robotic system, marking a significant step in the adoption of robotic-assisted cardiac care in the region.
The inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This collaboration highlights the potential of the SSi Mantra system to enable complex cardiac procedures with enhanced precision and minimally invasive techniques. According to a recent company video, Kings Hospital has already completed more than 25 robotic procedures in just three weeks, demonstrating rapid adoption and clinical confidence in the technology.
The significance of this launch extends beyond Sri Lanka's borders. It underscores the growing global reach of SS Innovations and the increasing acceptance of robotic surgery in diverse healthcare markets. As of the end of the second quarter, SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries. This expanding installed base is a testament to the system's versatility and effectiveness across different surgical specialties.
Financially, the company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528. This sharp rise in procedure volume points to rising utilization of the company's installed base, a key indicator of long-term recurring revenue potential. As more hospitals adopt the SSi Mantra system and surgeons become proficient in its use, the number of procedures is likely to continue climbing, driving further revenue growth.
The next major corporate milestone for SS Innovations is regulatory expansion. The company is actively pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open doors to two of the largest and most lucrative medical device markets in the world. It would also provide a significant competitive advantage, as regulatory approval from these bodies is often seen as a benchmark for quality and safety. Success in these endeavors could accelerate the company's growth trajectory and solidify its position in the global surgical robotics market.
For investors, the launch in Sri Lanka and the upcoming regulatory catalysts represent important developments. The ability to penetrate new markets and secure regulatory approvals are critical drivers of value in the medical technology sector. SS Innovations' progress in these areas will be closely watched. The company's newsroom at https://ibn.fm/SSII provides ongoing updates on these and other milestones.
In summary, the introduction of robotic cardiac surgery in Sri Lanka is more than a local healthcare achievement; it is a clear signal of SS Innovations' expanding global influence and the growing demand for its advanced surgical solutions. With a solid installed base, increasing procedure volumes, and pending regulatory clearances, the company is poised to make significant strides in the evolving field of robotic surgery.
